Localized insulin-like growth factor I delivery to enhance new bone formation

Bone. 2003 Oct;33(4):660-72. doi: 10.1016/s8756-3282(03)00207-2.

Abstract

Insulin-like growth factor I (IGF I) exerts an important role during skeletal growth and bone formation. Therefore, its localized delivery appears attractive for the treatment of bone defects. To prolong IGF I delivery, we entrapped the protein into biodegradable poly(lactide-co-glycolide) microspheres (PLGA MS) and evaluated the potential of this delivery system for new bone formation in two defect models of ovine long bones, i.e., a 8-mm methaphyseal drill hole and a 10-mm segmental tibia defect. Administration of 100 microg of IGF I in PLGA MS resulted in new bone formation within 3 weeks in the drill hole and bridging of the segmental defect within 8 weeks. The observed increase of 12% newly formed bone in the drill hole defect after 3 weeks was substantial, compared to the measured morphometric bone-to-total area ratio of 31% bone in normal cancellous bone. Bone regeneration was further explored by measuring gene expression of typical markers for local mediators and growth factors by real-time polymerase chain reaction. Inflammation was reduced in presence of IGF I and this in vivo observation was corroborated in vitro by quantifying gene expression of inflammatory proteins and by assessing the activation of the NF-kappaB pathway, playing an important role in the regulation of inflammation. Administration of the IGF I delivery system downregulated inflammatory marker gene expression at the site of bone injury, induced new bone formation and reduced bone resorption, and resulted in bridging of 10-mm segmental tibial defects within 8 weeks.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Diseases / drug therapy*
  • Bone Diseases / genetics
  • Bone Diseases / metabolism
  • Bone Diseases / pathology
  • Cells, Cultured
  • Cyclooxygenase 2
  • Drug Delivery Systems
  • Female
  • Fracture Healing / drug effects
  • Fracture Healing / genetics
  • Fracture Healing / physiology
  • Gene Expression / drug effects
  • Insulin-Like Growth Factor I / administration & dosage*
  • Interleukin-1 / genetics
  • Interleukin-6 / genetics
  • Isoenzymes / genetics
  • Microspheres
  • NF-kappa B / metabolism
  • Nitric Oxide Synthase / genetics
  • Nitric Oxide Synthase Type II
  • Osteoblasts / drug effects
  • Osteoblasts / metabolism
  • Osteogenesis / drug effects*
  • Prostaglandin-Endoperoxide Synthases / genetics
  • Recombinant Proteins / administration & dosage
  • Sheep

Substances

  • Interleukin-1
  • Interleukin-6
  • Isoenzymes
  • NF-kappa B
  • Recombinant Proteins
  • Insulin-Like Growth Factor I
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • Cyclooxygenase 2
  • Prostaglandin-Endoperoxide Synthases